BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/17/2017 8:32:00 AM | Browse: 1115 | Download: 2196
 |
Received |
|
2016-08-22 21:23 |
|
Peer-Review Started |
|
2016-08-24 08:50 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-10-08 09:58 |
|
Revised |
|
2016-10-23 16:13 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2017-01-04 15:56 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2017-01-14 14:30 |
|
Articles in Press |
|
2017-01-14 14:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-02-13 15:45 |
|
Publish the Manuscript Online |
|
2017-02-17 08:32 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Hiroto Wakabayashi, Shogo Ohkoshi, Takashi Tsukishiro, Toru Takahashi, Toshiaki Watanabe and Shuji Terai |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Grants-in-Aid for Scientific Research (C) (to Yamagiwa S) from Japan Society for the Promotion of Science (JSPS) |
15K08991 |
|
| Corresponding Author |
Satoshi Yamagiwa, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510,
Japan. syamagi@med.niigata-u.ac.jp |
| Key Words |
Telaprevir; Aged patients; Hepatitis C virus genotype 1b; Interleukin 28B; Simeprevir |
| Core Tip |
We evaluated the efficacy and safety of telaprevir (TVR)-and simeprevir (SMV)-based triple therapies for elderly patients with chronic hepatitis C, especially patients aged 66 years or older, in a real-world clinical setting. In both the TVR and SMV groups, no significant differences in the SVR and adverse events resulting in treatment discontinuation were found between the younger (aged ≤ 65) and older (aged > 65) patients. Both the TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with chronic hepatitis C virus genotype 1b infection. Ge-notyping of the interleukin-28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.
|
| Publish Date |
2017-02-17 08:32 |
| Citation |
Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262 |
| URL |
http://www.wjgnet.com/1948-5182/full/v9/i5/252.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v9.i5.252 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
